Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Could a New COVID Pill Crush Vaccine Sales?
Could a New COVID Pill Crush Vaccine Sales?
Could a New COVID Pill Crush Vaccine Sales?
Submitted by
admin
on October 5, 2021 - 10:45am
Source:
Motley Fool
News Tags:
Merck
COVID-19
vaccines
molnupiravir
Ridgeback Biotherapeutics
Headline:
Could a New COVID Pill Crush Vaccine Sales?
snippet:
Merck plans to request emergency authorization for its investigational coronavirus pill as soon as possible.
This would offer a treatment option for non-hospitalized patients with mild-to-moderate illness.
So far, about 55% of Americans are vaccinated against COVID-19.
Do Not Allow Advertisers to Use My Personal information